An observational study in Breast Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by City of Hope Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.
Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2026, is one of 12 observational ones, reaches primary completion later than 34 of the 38 other live ones, and was the 88th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 1 · Phase 4 1
First in 1994; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 423 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 36 across the 76 interventional studies, 219 across the 12 observational. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
13 of the studies in Breast Neoplasms by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04661982City of Hope Medical CenterLong Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer | 2026-11-24 |
| NCT01992432City of Hope Medical CenterBrain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC) | 2026-11-30 |
| NCT01450020City of Hope Medical CenterPeer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors | 2027-01-01 |
| NCT01824745City of Hope Medical CenterSurvivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors | 2027-01-01 |
| NCT07664579City of Hope Medical CenterInvestigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | 2027-01-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates patient and provider attitudes about environmental exposure risk assessments into clinical care for female patients at average or high risk for breast cancer and/or diagnosed with early onset breast cancer.
PRIMARY OBJECTIVES:
I. To assess patient interest and emotional responses toward EERA and return of results.
II. To assess provider attitudes toward EERA integration into clinical workflows.
OUTLINE: This is an observational study. Participants are assigned to 1 of 3 aims.
AIM I: Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.
AIM II: COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
AIM III: Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.
Female patients aged 18 years or older who either are considered average risk for developing breast cancer or high-risk for developing breast cancer or have early-onset breast cancer as well as providers at City of Hope.
Inclusion Criteria:
AIM 1 INCLUSION CRITERIA:
ONE of the following:
Willingness to:
AIM 2 INCLUSION CRITERIA
Willingness to:
AIM 3 INCLUSION CRITERIA:
ONE of the following:
Willingness to:
Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.
Other: Non-Interventional Study
COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.
Other: Non-Interventional Study
Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.
Other: Non-Interventional Study
Non-interventional study
Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Patient survey responses on perceived utility
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using analysis of covariance (ANCOVA). Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.
Time frame: Up to one year
Patient survey responses on willingness to engage
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.
Time frame: Up to one year
Patient survey responses on preferences for receiving EERA results
Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.
Time frame: Up to one year
Provider survey responses on perceived utility
Descriptive analysis will be used to examine all quantitative variables.
Time frame: Up to one year
Provider survey responses on feasibility
Descriptive analysis will be used to examine all quantitative variables.
Time frame: Up to one year
Provider survey responses on preferences for EERA disclosures into workflows
Descriptive analysis will be used to examine all quantitative variables.
Time frame: Up to one year
Proportion of participants who wear the work wristband for a total of 1 week
Feasibility will be defined as the proportion of participants who wear the work wristband for a total of 1 week. The feasibility rate will be summarized descriptively using point estimates and 95% confidence intervals.
Time frame: Up to one year
Chemical exposure measured by Fresh Air Clip wristband
Acceptability will be measured in the follow-up survey using the question: "Overall, how acceptable did you find wearing the 'Fresh Air clip' wristband to measure chemical exposures in your daily life?" Participants who respond "No opinion," "Acceptable," or "Completely acceptable" will be categorized as finding the wristband acceptable. The acceptability rate will be summarized descriptively using point estimates and 95% confidence intervals.
Time frame: Up to one year
Started Oct 2026 (actual). Primary completion is estimated for Feb 2029, 28 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 28 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 20, 2026.
Primary completion moved twice since we started tracking on Sep 25, 2026: Jan 2028 → Feb 2029, last on Oct 30, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Jan 2028 → Feb 2029, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.